Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...

Roche said CR-388 is ready to start phase 2 testing and will be developed for the treatment of obesity in people with and without type 2 diabetes. Like Zepbound and Novo Nordisk’s rival obesity ...

there are approximately 2.3 million new cases each year, and each year over 620,000 breast cancer patients will die. Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...